COVID-19 mAbs work best early: Data Byte

With a third and fourth antiviral mAb showing little benefit in hospitalized COIVD-19 patients this week, support is growing for the idea that this class of therapy is only effective when given early in disease.

VIR-7831 from Vir Biotechnology Inc. (NASDAQ:VIR) and partner GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) met the pre-specified criteria for continuing the next phase of NIH’s ACTIV-3 platform trial in hospitalized COVID patients, but the study’s DSMB recommended closing the VIR-7831 arm due to concerns about the mAb’s effect size arising from sensitivity analyses...